Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) and Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.
Analyst Ratings
This is a breakdown of recent recommendations for Nabriva Therapeutics and Hillstream Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nabriva Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Hillstream Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Given Nabriva Therapeutics’ higher possible upside, research analysts clearly believe Nabriva Therapeutics is more favorable than Hillstream Biopharma.
Risk and Volatility
Profitability
This table compares Nabriva Therapeutics and Hillstream Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nabriva Therapeutics | -148.11% | -365.53% | -135.81% |
| Hillstream Biopharma | N/A | -51.08% | -39.02% |
Insider and Institutional Ownership
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Nabriva Therapeutics and Hillstream Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nabriva Therapeutics | $35.59 million | 0.00 | -$57.19 million | ($19.20) | N/A |
| Hillstream Biopharma | N/A | N/A | -$35.92 million | ($3.99) | -0.94 |
Hillstream Biopharma has lower revenue, but higher earnings than Nabriva Therapeutics. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Hillstream Biopharma beats Nabriva Therapeutics on 8 of the 12 factors compared between the two stocks.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
About Hillstream Biopharma
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
